Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Sixty-one febrile episodes among 27 neutropenic patients with malignant hematological diseases were studied during a study period between 1998 and 2001. The results were compared with the previous 3-year period. The main differences in treatment were that we did not use ciprofloxacin prophylaxis routinely and we added granulocyte-macrophage colony-stimulating factor to the antimicrobial treatment regimen. The clinical and microbiological spectra of diseases shifted toward Gram-positive bacteremia and lower respiratory infections. The number and rate of infections and the mortality rate did not change significantly.
Rókusz
László
L
First Department of Medicine, Central Military Hospital of the Hungarian Defense Forces, 1553 P.f. 1, Budapest, Hungary.
László
Liptay
L
D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000009:adverse effects; D016470:Bacteremia / Q000382:microbiology; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D002939:Ciprofloxacin / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000382:microbiology; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D012189:Retrospective Studies; D012720:Severity of Illness Index
D000970:Antineoplastic Agents; D002939:Ciprofloxacin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor